Why Analytical Instruments and Pharma Services Organizations are Rethinking Incentive Design to Drive Competitive Growth
Sales compensation is the most powerful growth lever in analytical instruments and pharma services, yet it’s hiding in plain sight. With sales compensation, organizations can influence seller focus, time allocation and whether commercial effort turns into real productivity. When incremental growth is scarce, sales compensation becomes the mechanism that decides if teams displace competitors or simply recycle existing demand. For revenue leaders, there’s a looming question to answer:
How do you turn compensation investment into sustained, profitable growth when growth must be earned, and competition determines who captures it?
Leaders are already recognizing that their current approaches aren’t built for today’s competitive reality. In fact, 96% of companies in Alexander Group’s 2026 Sales Compensation Trends Survey plan to make changes this year. Rather than leaving incentives static, GTM leaders are reevaluating how incentive design can better direct seller focus, improve productivity and support growth that must be earned.
Let’s explore some key sales compensation plan changes that GTM leaders are making to help drive growth through the commercial team.
- Shifting pay mix toward greater variable to heighten accountability for incremental growth
- Richer upside to differentiate and retain top performers—not simply retain the middle
- Growth‑focused plan components to drive competitive displacement
1. Shifting Pay Mix Toward Greater Variable to Heighten Accountability for Incremental Growth
Over time, compensation structure in analytical instruments and pharma services has quietly drifted toward safety. Merit increases, fixed incentive targets and base-heavy pay structures (particularly in North America) have moved more earnings out of sellers’ control. Predictably, these designs attract the wrong talent, reward risk avoidance and reinforce farming behaviors at the exact moment growth must be earned. A base-heavy pay package may preserve stability, but it rarely produces urgency, competitive intensity or real growth. The average pay mix across pharma and biotech still sits around 69/31, nearly 70% of total target compensation locked into base salary. However, a subset of organizations have increasingly been pushing more aggressively toward variable pay to attract a more hunting‑oriented seller profile and deliberately compete for share in a tighter growth environment.
2. Richer Upside to Attract and Retain Top Talent, Not Simply Retain the Middle
As the battle for talent continues into 2026, commercial leaders are becoming far more intentional about where compensation dollars are invested. While competitive pay levels remain table stakes, leaders are increasingly using sales compensation to differentiate rewards for the performers who create incremental growth. In an environment where growth must be earned, plans are being redesigned to strengthen the connection between incentive upside and growth outcomes. This raises expectations for what it means to exceed target.
To remain competitive, organizations are adjusting plan mechanics to ensure top performers have meaningful upside and the opportunity to continue earning as growth compounds. Industry benchmarks reflect the shift, with 92% of organizations now uncapping their plans. Average high-performance pay has climbed to 2.6x target incentive, so top-decile performers earn roughly 260% of their variable target.
Before expanding upside, organizations should conduct robust plan costing and financial modeling. Careful evaluation of payout distribution, performance curves and funding mechanisms is essential to balance exposure across performance levels and preserve affordability. If done well, increased upside will deliver a compelling return: Incremental cost only materializes when incremental growth is achieved, making upside one of the most efficient investments commercial leaders can make.
3. Growth‑Focused Plan Components to Drive Competitive Displacement
Long-term growth in analytical instruments and pharma services doesn’t come from doing more of the same. Organizations achieve growth by deliberately redirecting seller effort toward competitive wins. Too often, legacy compensation plans anchor sellers to core brands and existing demand, reinforcing coverage and continuity rather than growth. Leading organizations are breaking that pattern by embedding hunting-focused constructs directly into plan design. These shifts can range from targeted SPIFFs that accelerate short-term priorities to fundamental changes in plan measures that redefine what “success” looks like in the field.
At the core, the challenge is consistent: How do you use sales compensation to push sellers beyond the core, diversify effort toward growth opportunities, and create sustained competitive focus—rather than incremental redistribution of existing demand?
In practice, there are three key shifts Alexander Group is observing as leading practices to drive growth:
- Introducing components for new customer acquisition to reward true displacement
- Adding cross-sell measures to drive focus on expanding share of wallet
- Shift crediting from lagging billings to upfront bookings to emphasize deal creation and future growth
Done well, these hunting-focused plan changes don’t just encourage different behavior, but they realign the field around growth.
The Plan Decides Who Grows
In low-growth markets, sales compensation has transitioned from an administrative exercise to a strategic choice. The organizations that outgrow the market will not be the ones that make incremental tweaks or chase short‑term incentives. They will deliberately redesign compensation to direct seller effort toward competitive wins, higher productivity, and sustainable growth. As analytical instruments and pharma services leaders look ahead, they must examine whether their plans are intentionally built to capture the growth. Those who get it right will take share, but those who don’t will simply defend what they already have.
